Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BHSTNASDAQ:ENTANASDAQ:MTCRNASDAQ:XBIT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHSTBioHarvest Sciences$6.27-1.3%$6.15$6.25▼$7.38$102.99M0.817,070 shs8,890 shsENTAEnanta Pharmaceuticals$5.97-3.1%$5.39$4.09▼$17.24$127.62M0.81285,101 shs176,864 shsMTCRMetacrine$0.58$0.57$0.30▼$0.59$24.75M-0.73225,834 shs83,889 shsXBITXBiotech$2.84-0.7%$3.00$2.65▼$8.32$86.59M0.9874,103 shs41,389 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHSTBioHarvest Sciences-1.26%-0.32%-2.64%+19.66%+626,999,900.00%ENTAEnanta Pharmaceuticals-3.08%+2.75%-1.97%-23.26%-49.83%MTCRMetacrine0.00%0.00%0.00%0.00%0.00%XBITXBiotech-0.70%0.00%-6.58%-19.32%-61.47%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHSTBioHarvest SciencesN/AN/AN/AN/AN/AN/AN/AN/AENTAEnanta Pharmaceuticals3.8987 of 5 stars3.41.00.04.73.42.50.0MTCRMetacrineN/AN/AN/AN/AN/AN/AN/AN/AXBITXBiotech1.2934 of 5 stars0.03.00.00.03.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHSTBioHarvest Sciences 3.00Buy$13.67117.97% UpsideENTAEnanta Pharmaceuticals 2.80Moderate Buy$17.25188.94% UpsideMTCRMetacrine 0.00N/AN/AN/AXBITXBiotech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MTCR, BHST, ENTA, and XBIT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2025BHSTBioHarvest SciencesCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.004/8/2025BHSTBioHarvest SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHSTBioHarvest Sciences$27.70M3.72N/AN/A($1.08) per share-5.81ENTAEnanta Pharmaceuticals$64.46M1.98N/AN/A$5.24 per share1.14MTCRMetacrineN/AN/AN/AN/A$1.36 per shareN/AXBITXBiotech$4.01M21.59N/AN/A$7.19 per share0.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHSTBioHarvest Sciences-$12.56M-$0.50N/AN/AN/A-76.65%N/A-85.16%N/AENTAEnanta Pharmaceuticals-$116.04M-$4.54N/AN/AN/A-157.57%-75.53%-27.30%8/4/2025 (Estimated)MTCRMetacrine-$62.21M-$1.03N/A∞N/AN/A-84.88%-59.33%N/AXBITXBiotech-$24.56M-$1.29N/A∞N/AN/A-15.99%-14.85%8/11/2025 (Estimated)Latest MTCR, BHST, ENTA, and XBIT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025BHSTBioHarvest Sciences-$0.15-$0.13+$0.02-$0.13$8.93 million$7.64 million5/14/2025Q1 2025XBITXBiotechN/A-$0.36N/A-$0.36N/AN/A5/12/2025Q2 2025ENTAEnanta Pharmaceuticals-$1.04-$1.06-$0.02-$1.06$15.96 million$14.93 million3/31/2025Q4 2024BHSTBioHarvest Sciences-$0.12-$0.17-$0.05-$0.17$7.24 million$7.17 million3/18/2025Q4 2024XBITXBiotechN/A-$0.34N/A-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHSTBioHarvest SciencesN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AMTCRMetacrineN/AN/AN/AN/AN/AXBITXBiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHSTBioHarvest SciencesN/A0.800.48ENTAEnanta PharmaceuticalsN/A5.475.47MTCRMetacrine0.3412.1512.15XBITXBiotechN/A11.5711.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHSTBioHarvest SciencesN/AENTAEnanta Pharmaceuticals94.99%MTCRMetacrine37.72%XBITXBiotech55.70%Insider OwnershipCompanyInsider OwnershipBHSTBioHarvest SciencesN/AENTAEnanta Pharmaceuticals13.89%MTCRMetacrine13.80%XBITXBiotech33.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHSTBioHarvest SciencesN/A16.43 millionN/AN/AENTAEnanta Pharmaceuticals16021.38 million18.37 millionOptionableMTCRMetacrine1042.57 million36.70 millionNot OptionableXBITXBiotech10030.49 million20.39 millionOptionableMTCR, BHST, ENTA, and XBIT HeadlinesRecent News About These CompaniesXBiotech (NASDAQ:XBIT) Share Price Crosses Below 50-Day Moving Average - What's Next?May 25, 2025 | marketbeat.comXBiotech (NASDAQ:XBIT) Stock Crosses Below 50 Day Moving Average - What's Next?May 17, 2025 | marketbeat.comXBiotech (NASDAQ:XBIT) Share Price Crosses Below 50-Day Moving Average - Time to Sell?May 2, 2025 | marketbeat.comThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationMarch 2, 2025 | accessnewswire.comAn Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmMarch 1, 2025 | accessnewswire.comThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 28, 2025 | accessnewswire.comAn Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 27, 2025 | accessnewswire.comThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 26, 2025 | accessnewswire.comAn Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 25, 2025 | accessnewswire.comThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 24, 2025 | accessnewswire.comAn Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 23, 2025 | accessnewswire.comThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 22, 2025 | accessnewswire.comAn Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 21, 2025 | accessnewswire.comThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 20, 2025 | accessnewswire.comThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 18, 2025 | accessnewswire.comXBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 17, 2025 | accessnewswire.comThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 16, 2025 | accessnewswire.comXBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 15, 2025 | accessnewswire.comThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 14, 2025 | accessnewswire.comXBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 13, 2025 | accessnewswire.comThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 12, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Undervalued Stocks Wall Street Is Getting WrongBy Gabriel Osorio-Mazilli | May 12, 2025View 3 Undervalued Stocks Wall Street Is Getting WrongSavvy Investors Are Raising a Glass for Heineken StockBy Chris Markoch | May 18, 2025View Savvy Investors Are Raising a Glass for Heineken StockIs It Time to Buy the Dip in Novo Nordisk Stock?By Chris Markoch | May 15, 2025View Is It Time to Buy the Dip in Novo Nordisk Stock?Is Reddit Stock a Buy, Sell, or Hold After Earnings Release?By Gabriel Osorio-Mazilli | May 5, 2025View Is Reddit Stock a Buy, Sell, or Hold After Earnings Release?Is NIO Stock Set for a Comeback? Fundamentals Say YesBy Gabriel Osorio-Mazilli | May 19, 2025View Is NIO Stock Set for a Comeback? Fundamentals Say YesMTCR, BHST, ENTA, and XBIT Company DescriptionsBioHarvest Sciences NASDAQ:BHST$6.27 -0.08 (-1.26%) As of 05/30/2025 03:58 PM EasternBioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.Enanta Pharmaceuticals NASDAQ:ENTA$5.97 -0.19 (-3.08%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$5.93 -0.04 (-0.74%) As of 05/30/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Metacrine NASDAQ:MTCRMetacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.XBiotech NASDAQ:XBIT$2.84 -0.02 (-0.70%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$2.85 +0.01 (+0.35%) As of 05/30/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
